Hosted on MSN3h
We Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug Wars
Shares of Eli Lilly finished Thursday 3% higher despite an earnings report that showed sales of its blockbuster GLP-1 ...
Trump's Greenland dreams could ding huge North Carolina employer
Trump's threat of imposing a tariff on Denmark over desires to acquire Greenland has caught the attention of one of the ...
Ozempic Could Get Way Too Expensive Under Trump—Here's What You Can Do
While it may seem strange that politics could impact the price of popular weight loss drugs, it is a definite possibility.
The Obesity Market Is Growing Just Fine. But Investors Want to Know What’s Next
Eli Lilly and Novo Nordisk have both assuaged investor concerns over near-term growth. Now the focus shifts back to their ...